FTC reasonable-basis doctrine: advertisers must possess "the amount and type of substantiation the ad actually communicates"

Claim: The FTC's Policy Statement on Advertising Substantiation (1984, building on a 1971 line of decisions): advertisers must possess "the amount and type of substantiation the ad actually communicates to consumers" for any objective ad claim. Section 5 of the FTC Act remains the enforcement basis.

Source: https://ftc.gov Substantiation Statement; FTC training materials.

Confidence: Verified.

Specific phrases that trigger heightened substantiation thresholds:

"Tests Prove... Doctors Recommend... Studies Show..."

Source: FTC training materials — https://ftc.gov/sites/default/files/attachments/training-materials/substantiation.pdf

The operational implication: the phrase "studies show" in marketing copy without a specific named study is not just a sourcing failure — it is potentially FTC-actionable. The reader's instinct that "studies show" is a tell of unsourced claims aligns with FTC enforcement reality.

Status in 2026: Xlear v. FTC litigation (filed late 2024, citing Loper Bright Enterprises v. Raimondo, 2024) is challenging the doctrine. Absent injunction, the doctrine remains in full force as of May 2026. Monitor for outcome.

For Canadian clients: FTC enforcement is US-only, but the substantiation principle applies via comparable Canadian rules (Competition Bureau's "general impression test" under the Competition Act, plus CRTC and provincial consumer-protection statutes). The discipline is portable; the legal mechanism differs.